SCHEMBL12412463

SCHEMBL12412463

CC(C)NC(=O)CCN1C(=O)C=CC1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
PTGS1 P23219 4/20 0.43
PTGS2 P35354 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 2/20 0.43
FAAH O00519 3/20 0.42
MGLL Q99685 3/20 0.42
MAPK1 P28482 2/20 0.42
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
LMNA P02545 2/20 0.41
HSP90AA1 P07900 1/20 0.41
TLR9 Q9NR96 1/20 0.41
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
XBP1 P17861 1/20 0.41
HTT P42858 1/20 0.41
RECQL P46063 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16724823 0.89 KDM4E (0.40) KDM4EPTGS1PTGS2MEN1KMT2A
SCHEMBL12401794 0.87 MEN1 (0.43) KDM4EPTGS1PTGS2MEN1KMT2A
SCHEMBL17721377 0.87 PTGS1 (0.58) KDM4EPTGS1PTGS2MEN1KMT2A
SCHEMBL23506482 0.86 PTGS1 (0.41) PTGS1PTGS2MAPTFAAHMGLL
SCHEMBL24722846 0.85 KDM4E (0.48) KDM4EPTGS1PTGS2KMT2AMAPT
SCHEMBL14865037 0.85 CNR2 (0.41) PTGS1PTGS2MAPTFAAHMGLL
SCHEMBL24722840 0.85 KDM4E (0.48) KDM4EPTGS1PTGS2KMT2AMAPT
SCHEMBL12508170 0.85 PTGS1 (0.40) KDM4EPTGS1PTGS2MAPTFAAH
SCHEMBL22538847 0.83 PTGS1 (0.39) KDM4EPTGS1PTGS2MAPTFAAH
SCHEMBL12107736 0.83 PTGS1 (0.39) KDM4EPTGS1PTGS2MAPTFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287030-A1 Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions THE GENERAL HOSPITAL CORPORATION 2023-09-14 US disclosed
US-20220409697-A1 Extended Half-life G-CSF and GM-CSF Vitamin D Conjugates RAMEA LLC (US) 2022-12-29 US disclosed
EP-3949969-A2 BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF Silverback Therapeutics, Inc. (US) 2022-02-09 EP disclosed
EP-3760639-A1 ZWITTERIONIC POLYMER CONJUGATES Kodiak Sciences Inc. (US) 2021-01-06 EP disclosed
US-20170246313-A1 AN IMPROVED PROCESS OF CONJUGATION AND NOVEL SYNTHETIC OLIGOSACCHARIDE- PROTEIN CONJUGATES OBTAINED THEREOF MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD. (IN) 2017-08-31 US disclosed
WO-2017095805-A1 ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE ABBVIE INC. (US) 2017-06-08 WO disclosed
US-20170145112-A1 ANTI-FACTOR D ANTIBODIES AND CONJUGATES GENENTECH, INC. (US) 2017-05-25 US disclosed
US-9650363-B2 Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1 HOFFMANN-LA ROCHE INC. (US) 2017-05-16 US disclosed
US-9586916-B2 Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3 HOFFMANN-LA ROCHE INC. (US) 2017-03-07 US disclosed
US-20170058031-A1 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF SQUIBB & SONS LLC (US) 2017-03-02 US disclosed
US-9116128-B2 Click chemistry surface functionalization for resonant micro-cavity sensors CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2015-08-25 US disclosed
US-20150139901-A1 Radioactive Rhodium Complexes, Preparation Methods and Uses Thereof INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE (INSERM) (FR) 2015-05-21 US disclosed
US-20110171164-A1 POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed
US-20110165112-A1 POLYMER CONJUGATES OF C-PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed
US-20110165112-A1 POLYMER CONJUGATES OF C-PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150139901-A1 Radioactive Rhodium Complexes, Preparation Methods and Uses Thereof RAB35, MRPL21, MRPS35 KDM4E 3684/4885PTGS1 4878/4885PTGS2 4875/4885
US-20110165112-A1 POLYMER CONJUGATES OF C-PEPTIDES IAPP, GCG, INSR KDM4E 4796/4885PTGS1 4217/4885PTGS2 4578/4885
US-20170058031-A1 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF CD2BP2, CD22, CD2 KDM4E 3321/4885PTGS1 4481/4885PTGS2 3118/4885
US-20220409697-A1 Extended Half-life G-CSF and GM-CSF Vitamin D Conjugates CSF3R, CYP24A1, GC KDM4E 2698/4885PTGS1 1056/4885PTGS2 1376/4885
US-20170145112-A1 ANTI-FACTOR D ANTIBODIES AND CONJUGATES CFD, F13B, CFH KDM4E 2617/4885PTGS1 2141/4885PTGS2 2605/4885
US-20230287030-A1 Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions GALNT14, NEU4, CSGALNACT1 KDM4E 933/4885PTGS1 2107/4885PTGS2 2044/4885
US-20110171164-A1 POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES IAPP, GLP1R, GIPR KDM4E 3559/4885PTGS1 3371/4885PTGS2 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.